These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 21271749)

  • 1. Influence of patient co-payments on atypical antipsychotic choice in Poland: implications once generic atypicals are available.
    Wladysiuk M; Araszkiewicz A; Godman B; Szabert K; Barbui C; Haycox A
    Appl Health Econ Health Policy; 2011 Mar; 9(2):101-10. PubMed ID: 21271749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generic atypical antipsychotic drugs in Belgium: their influence and implications.
    Godman B; De Bruyn K; Miranda J; Raschi E; Bennie M; Barbui C; Simoens S
    J Comp Eff Res; 2013 Nov; 2(6):551-61. PubMed ID: 24236794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications.
    Godman B; Petzold M; Bennett K; Bennie M; Bucsics A; Finlayson AE; Martin A; Persson M; Piessnegger J; Raschi E; Simoens S; Zara C; Barbui C
    BMC Med; 2014 Jun; 12():98. PubMed ID: 24927744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications.
    Bennie M; Bishop I; Godman B; Barbui C; Raschi E; Campbell S; Miranda J; Gustafsson LL
    Int J Clin Pract; 2013 Feb; 67(2):170-80. PubMed ID: 23305478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug prescription patterns in schizophrenia outpatients: analysis of data from a German health insurance fund.
    Weinbrenner S; Assion HJ; Stargardt T; Busse R; Juckel G; Gericke CA
    Pharmacopsychiatry; 2009 Mar; 42(2):66-71. PubMed ID: 19308881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical antipsychotic use for adult outpatients in New Zealand's Auckland and Northland regions.
    Wheeler A
    N Z Med J; 2006 Jul; 119(1237):U2055. PubMed ID: 16862201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generic olanzapine: health authority opportunity or nightmare?
    Araszkiewicz AA; Szabert K; Godman B; Wladysiuk M; Barbui C; Haycox A
    Expert Rev Pharmacoecon Outcomes Res; 2008 Dec; 8(6):549-55. PubMed ID: 20528365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of co-morbidities with prescribing patterns and cost savings: olanzapine versus risperidone for schizophrenia.
    Yu W; Ren XS; Lee AF; Herz L; Huang YH; Kazis LE
    Pharmacoeconomics; 2006; 24(12):1233-48. PubMed ID: 17129077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.
    Mladsi DM; Grogg AL; Irish WD; Lopez RB; Degen K; Swann A; Nimsch CT
    Curr Med Res Opin; 2004 Dec; 20(12):1883-93. PubMed ID: 15701206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of institutional fiscal stress on the use of atypical antipsychotic medications in the treatment of schizophrenia.
    Leslie DL; Rosenheck R
    J Nerv Ment Dis; 2001 Jun; 189(6):377-83. PubMed ID: 11434638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Forecasting Medicaid Expenditures for Antipsychotic Medications.
    Slade EP; Simoni-Wastila L
    Psychiatr Serv; 2015 Jul; 66(7):713-8. PubMed ID: 25828875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications.
    McGinn D; Godman B; Lonsdale J; Way R; Wettermark B; Haycox A
    Expert Rev Pharmacoecon Outcomes Res; 2010 Feb; 10(1):73-85. PubMed ID: 20121565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of safety warnings in atypical antipsychotic drugs: an interrupted time-series analysis in Spain.
    Sanfélix-Gimeno G; Cervera-Casino P; Peiró S; López-Valcarcel BG; Blázquez A; Barbera T
    Drug Saf; 2009; 32(11):1075-87. PubMed ID: 19810779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European countries with small populations can obtain low prices for drugs: Lithuania as a case history.
    Garuoliene K; Godman B; Gulbinovič J; Wettermark B; Haycox A
    Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):343-9. PubMed ID: 21671703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initiatives in South Africa to enhance the prescribing of generic proton pump inhibitors: findings and implications.
    Truter I; Shankar S; Bennie M; Woerkom Mv; Godman B
    J Comp Eff Res; 2015 Mar; 4(2):123-31. PubMed ID: 25825841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescribing efficiency of proton pump inhibitors in China: influence and future directions.
    Zeng W; Finlayson AE; Shankar S; de Bruyn W; Godman B
    BMC Health Serv Res; 2015 Jan; 15():11. PubMed ID: 25609265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in the prescribing of antipsychotic medicines in Pakistan: implications for the future.
    Mahmood S; Hussain S; Ur Rehman T; Barbui C; Kurdi AB; Godman B
    Curr Med Res Opin; 2019 Jan; 35(1):51-61. PubMed ID: 30122062
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.
    Yang YK; Tarn YH; Wang TY; Liu CY; Laio YC; Chou YH; Lee SM; Chen CC
    Psychiatry Clin Neurosci; 2005 Aug; 59(4):385-94. PubMed ID: 16048443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doctors who take company cash are more likely to prescribe brand name drugs, analysis finds.
    McCarthy M
    BMJ; 2016 Mar; 352():i1645. PubMed ID: 27000964
    [No Abstract]   [Full Text] [Related]  

  • 20. Changes in the utilization of venlafaxine after the introduction of generics in Sweden.
    Godman B; Persson M; Miranda J; Skiöld P; Wettermark B; Barbui C; Gustafsson LL
    Appl Health Econ Health Policy; 2013 Aug; 11(4):383-93. PubMed ID: 23754677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.